Compare Sana Biotechnology Inc (SANA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs ProShares UltraPro S&P500 — how do they compare? Sana Biotechnology Inc trades at $3.85 (market cap $1.13B), while ProShares UltraPro S&P500 trades at $154.8. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | UPRO | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $5.92 | $155.10 |
52-Week Low | $2.68 | $89.29 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
UPRO, a leveraged ETF tracking the S&P 500, trades at $154.9 with a slight 0.06% decline. Technical indicators show a bullish trend with strong moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Support lies at $152, with resistance at $155. Recent news highlights institutional buying and S&P 500 volatility amid inflation data and AI-driven earnings optimism.
The outlook for UPRO hinges on S&P 500 momentum, with bullish technicals but overbought risks. Upside potential exists if the index breaks resistance, but high leverage amplifies losses during pullbacks. Key risks include market volatility, inflation concerns, and stretched valuations. Investors should weigh the ETF's leveraged structure against broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
